WithdrawnPHASE1, PHASE2NCT04181359
The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.
Studying Interstitial lung disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alberta
- Principal Investigator
- Giovanni Ferrara, MDUniversity of Alberta
- Intervention
- Nitric Oxide(drug)
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2024 – 2026
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04181359 on ClinicalTrials.govOther trials for Interstitial lung disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07283081Impact of Capillaroscopy in the Investigation of Diffuse Interstitial PneumoniasUniversity Hospital, Bordeaux
- RECRUITINGNANCT07254338Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific Pulmonary Hypertension TreatmentHospices Civils de Lyon
- RECRUITINGNANCT07301697Safety and Performance Profile of Cryobiopsy in Bronchial EndoscopyUniversity Hospital, Strasbourg, France
- RECRUITINGNANCT07300696Functional MRI for Monitoring Progression and Assessing Trends in ILDUniversity Hospital Heidelberg
- RECRUITINGPHASE2NCT06053164Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung DiseaseUniversity of Alberta
- RECRUITINGNCT05819385Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)Boehringer Ingelheim
- RECRUITINGNCT06948942Exercise Capacity, Muscle Oxygenation, and Physical Activity Between Patients With Interstitial Lung DiseaseGazi University
- RECRUITINGNCT06235645dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasoundUniversity Hospital, Tours